Cancer Cell Nanotubes Hijack Mitochondria from Immune Sentinels

The mitochondria stolen via these tiny connections give tumor cells a metabolic boost while the T cells are left weakened, according to in vitro experiments.

Written bySophie Fessl, PhD
| 3 min read
Scanning electron micrograph showing cancer cell attached to T call via nanotube
Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Cancer cells send out nanotubes to suck mitochondria from immune cells, finds a November 18 study in Nature Nanotechnology. The pilfered organelles allow the cancer cells to replenish their power while weakening T cells—a finding that could lead to new avenues for assailing tumors.

“It’s surprising that the transfer of mitochondria happened between different cell types, intriguingly between immune cells and cancer cells,” writes cancer biologist Ming Tan of China Medical University in Taiwan, who was not involved in this study, in an email to The Scientist. While researchers have observed mitochondrial transfer between cells before, most cases occurred between two cells of the same type. “Moreover, the mitochondrial transfer appears to have a significant impact on tumor cells escaping from immune surveillance,” Tan adds. “This is exciting because [of] its potential therapeutic implications.”

Shiladitya Sengupta and colleagues at Brigham and Women’s Hospital and MIT, including co-corresponding author Hae Lin ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Headshot of Sophie Fessl

    Sophie Fessl is a freelance science journalist. She has a PhD in developmental neurobiology from King’s College London and a degree in biology from the University of Oxford. After completing her PhD, she swapped her favorite neuroscience model, the fruit fly, for pen and paper.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies